Allegra Orthopaedics Ltd (ASX:AMT) is continuing to make significant progress with its unique bone substitute technology “Sr-HT-Gahnite” and is aiming to progress into the production phase.
The company is an orthopaedic manufacturer and has obtained the global license to the composite biocompatible ceramic material known as Sr-HT- Gahnite from the University of Sydney.
Allegra’s tests have indicated that all the samples containing the Sr-HT Gahnite scaffolds showed promising ingrowth of bone through the scaffold and in some cases completely bridged the defect.
Importantly, there was no evidence of inflammation or formation of fibrous tissue, indicating good biocompatibility of the Sr-HT Gahnite.
The company is also studying the various commercial applications of this unique bone substitute technology, before commencing with interbody cervical spinal cages as the initial product offering.
Allegra’s bone project has the potential to be the world’s first fully synthetic spinal cage that can regenerate bone and be completely absorbed, leaving the body free of foreign materials.
The bone project has reached a stage where it has progressed from a successful laboratory environment and is moving toward commercial manufacturing.
Consequently, Allegra is now setting up a GMP (Good Manufacturing Practice) pilot manufacturing facility in Sydney, with the capability to manufacture the 3D printed spinal cages.
Allegra’s principal product, the Active Total Knee also remains a focussed product line for the company.